当前位置:
首页
网刊
B细胞淋巴因子-2抑制剂venetoclax的药理作用与临床评价
B细胞淋巴因子-2抑制剂venetoclax的药理作用与临床评价
王学阳1,2,封宇飞1,胡 欣1

1 北京医院 国家老年医学中心 药学部,北京 100730; 2 北京大学药学院药事管理与临床药学系,北京 100083
Pharmacological and clinical evaluation of venetoclax-BCL-2 inhibitor in the treatment of chronic lymphocytic leukemia
(1 Department of Pharmacy, Beijing Hospital,National Center of Gerontology, Beijing 100730,China; )

摘要参考文献相关文章

起始页:1473

摘要:[摘要] Venetoclax是一种口服的B细胞淋巴因子-2选择性抑制剂,主要用于治疗染色体异常删除突变del17p、且曾至少接受过1次化疗的慢性淋巴细胞白血病。常见的不良反应为腹泻、恶心、上呼吸道感染、中性粒细胞减少及疲劳等。本文对其药理作用、药动学、临床评价、安全性、用法用量和药物相互作用进行综述。

关键词:[关键词] venetoclax;慢性淋巴细胞白血病;B细胞淋巴因子-2抑制剂;药理作用;临床评价

通讯作者:[通讯作者] 封宇飞,男,主任药师,主要从事医院药学工作。联系电话: (010) 85133923,E-mail: fengyufei@126.com。

基金项目:

作者简介:

Abstract:[Abstract] Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2. It is mainly indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, who have received at least one prior therapy. The most common adverse events were diarrhea, nausea, upper respiratory tract infection, neutropenia, and fatigue. The pharmacology, pharmacokinetics, clinical research, safety, dosage, and drug interactions of venetoclax were reviewed in this paper.

Key words:[Key words] venetoclax; chronic lymphocytic leukemia; B-cell lymphoma factor 2(BCL-2) inhibitor; pharmacology; clinical evaluation

    [1] HALLEK M. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment[J]. Am J Hematol, 2013,88(9):803-816.
    [2] ROZMAN C, MONTSERRAT E. Chronic lymphocytic leukemia[J]. N Engl J Med, 1995,333(16):1052-1057. 
    [3] JAGLOWSKI S, JONES JA. Choosing first-line therapy for chronic lymphocytic leukemia[J]. Expert Rev Anticancer Ther, 2011,11(9): 1379-1390.
    [4] ZWIEBEL JA, CHESON BD. Chronic lymphocytic leukemia: staging and prognostic factors[J]. Semin Oncol,1998, 25(1): 42-59.
    [5] FDA. Venclexta[EB/OL].[2016-04-11](2016-08-22). http://www.rxlist.com/venclexta-drug/clinical-pharmacology.htm.
    [6] 张志叶,夏阳. 治疗慢性淋巴细胞白血病新药venetoclax

    [J].今日药学,2017,27(3):214-216.
    [7] WILLIS S, DAY CL, HINDS MG, et al. The Bcl-2-regulated apoptotic pathway[J]. J Cell Sci,2003, 116(Pt 20): 4053-4056.
    [8] CORY S, ADAMS JM. The Bcl2 family: regulators of the cellular life-ordeath switch[J]. Nat Rev Cancer, 2002, 2(9): 647-656.
    [9] HALLEK M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies[J].Blood, 2013, 122(23):3723-3734.
    [10] CZABOTAR PE, LESSENE G, STRASSER A, et al. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy[J]. Nat Rev Mol Cell Biol,2014,15(1): 49-63.
    [11] HUANG DC, STRASSER A. BH3-only proteins-essential initiators of apoptotic cell death[J]. Cell,2000, 103(6): 839-842.
    [12] DESAI AV, EL-BAKKAR H, ABDUL-HAY M. Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future[J]. Clinical Lymphoma Myeloma & Leukemia, 2014, 15(6): 314-322.
    [13] CANG S, IRAGAVARAPU C, SAVOOJI J, et al. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development[J]. J Hematol Oncol, 2015, 8(1): 1-8.
    [14] SOUERS AJ, LEVERSON JD, BOGHAERT ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets[J]. Nat Med,2013, 19(2): 202-208.
    [15] FDA.venetoclax[EB/OL].[2016-07-13]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208573s000lbl.pdf.
    [16] ROBERTS AW, DAVIDS MS, PAGEL JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia[J]. N Engl J Med, 2016, 374(4):311-322.
    [17] LEVERSON JD, KONOPLEVA M, POLLYEA DA, et al. A phase 2 study of ABT-199 (GDC-0199) in patients with acute myelogenous leukemia (AML)[C].San Francisco: American Society of Hematology 56th Annual Meeting, 2014:124.
    [18] SEYMOUR JF, DAVIDS MS, PAGEL JM, et al. ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): high completeresponse rate and durable disease control

    [C]. Chicago: ASCO Meeting Abstr.,2014,32(15_suppl): 7015.
    [19] DAVIDS MS, SEYMOUR JF, GERECITANO JF, et al. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses

    [C]. Chicago: ASCO Meeting Abstr., 2014,32(15_suppl): 8522.